Insulin dimer-incretin (Merck Sharp & Dohme)

N/A

Report date: 2026/04/09 20:00:21
NME

Base Information

Drug NameInsulin dimer-incretin (Merck Sharp & Dohme)
Drug Alias NameN/A
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGlucagon receptor agonistsInsulin receptor agonistsGlucagon-like peptide 1 receptor agonists
TargetsGlucagon receptorInsulin receptorGlucagon-like peptide 1 receptor
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMerck Sharp & Dohme LLC
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme LLC
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A